CoChat

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Open access
Bray, Steven M., Lee, Jeeyun, Kim, Seung Tae, Hur, Joon Young, Ebert, Philip J., Calley, John N., Wulur, Isabella H., Gopalappa, Thejaswini, Wong, Swee Seong, Qian, Hui-Rong, Ting, Jason C., Liu, Jiangang, Willard, Melinda D., Novosiadly, Ruslan D., Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong, Kang, Won Ki, Aggarwal, Amit, Kim, Hee Cheol, Reinhard, Christoph · 2019 · Scientific Reports
Cited by 82

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients receiving cetuximab (an EGFR inhibitor). Of 25 CRC patients, 13 displayed intrinsic resistance to cetuximab; 12 were intrinsically sensitive. We obtained six re-biopsy samples at acquired resistance from the intrinsically sensitive patients. NCOA4–RET and LMNA–NTRK1 fusions and NRG1 and GNAS amplifications were found in intrinsic-resistant patients. In cetuximab-sensitive patients, we found KRAS K117N and A146T mutations in addition to BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. The comparison between baseline and acquired-resistant tumours revealed an extreme shift in variant allele frequency of somatic variants, suggesting that cetuximab exposure dramatically selected for rare resistant subclones that were initially undetectable. There was also an increase in epithelial-to-mesenchymal transition at acquired resistance, with a reduction in the immune infiltrate. Furthermore, characterization of an acquired-resistant, patient-derived cell line showed that PI3K/mTOR inhibition could rescue cetuximab resistance. Thus, we uncovered novel genomic alterations that elucidate the mechanisms of sensitivity and resistance to anti-EGFR therapy in metastatic CRC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-51981-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 82

Metadata

Authors
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., Ting, J. C., Liu, J., Willard, M. D., Novosiadly, R. D., Park, Y. S., Park, J. O., Lim, H. Y., Kang, W. K., Aggarwal, A., Kim, H. C., & Reinhard, C.
Venue
Scientific Reports
Published
2019-10-25
Volume
9
Issue
1
Pages
15365-15365
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2981692546
Cited by
82
References
16
FWCI
3.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. https://app.cochat.ai/papers/10.1038/s41598-019-51981-5
The paper
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., Ting, J. C., Liu, J., Willard, M. D., Novosiadly, R. D., Park, Y. S., Park, J. O., Lim, H. Y., Kang, W. K., Aggarwal, A., . . . Reinhard, C. (2019). Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports. https://doi.org/10.1038/s41598-019-51981-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.